BC Week In Review | Oct 19, 2018
Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
BC Extra | Oct 17, 2018
Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
BC Innovations | Jul 23, 2015
Distillery Therapeutics

Therapeutics: Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115)

Neurology INDICATION: Neuroinflammation Mouse studies suggest the CSF1R inhibitor PLX3397 could help treat brain injury-induced neuroinflammation. CSF1R is expressed only on microglial cells in the brain and induces their proliferation. In a mouse model of...
BC Week In Review | Jun 30, 2014
Clinical News

RO5509554: Phase I/II data

Data from 18 evaluable patients with inoperable progressive or relapsing pigmented villonodular synovitis (PVNS) in the open-label, dose-escalation, French Phase Ia/Ib BP27772 trial or an extension cohort of the trial showed that IV RG7155 every...
BioCentury | Nov 11, 2013
Strategy

New York translation

Now headquartered at the newly opened Translational Clinical Research Center in New York, Roche 's Pharma Research & Early Development organization has undergone another retooling intended to increase its efficiency and productivity. The center will...
BC Innovations | Oct 31, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) Mouse studies suggest the brain-penetrant CSF1R inhibitor BLZ945 could be used to treat glioblastoma multiforme (GBM)....
Items per page:
1 - 6 of 6